Literature DB >> 7506108

A review on the acute phase response in major depression.

M Maes1.   

Abstract

There is some evidence that major depression is characterized by systemic immune activation with involvement of phagocytic cells, T cell activation, B cell proliferation and increased autoantibody production. This paper reviews that major depression may be accompanied by higher concentrations of positive and lower concentrations of negative acute phase proteins (APPs). The most prominent abnormalities of APPs in major depression are increased haptoglobin (Hp) plasma levels. The latter are significantly and positively correlated with interleukin (IL)-6 production, various indices of systemic immune activation (e.g. monocytosis, neutrophilia, T cell activation) and with the vegetative symptoms of depression (e.g. anorexia, weight loss, psychomotor retardation, sleep disorders, anergy). Major depression is characterized by an altered distribution of Hp phenotypes and genes suggesting that genetic variation on chromosome 16 may be associated with this illness. It is concluded that increased production of IL-6 and IL-1 in major depression may underlie both immune activation and the "acute" phase response in that illness, and that disorders in Hp may be related to the pathophysiology and pathogenesis of major depression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506108     DOI: 10.1515/revneuro.1993.4.4.407

Source DB:  PubMed          Journal:  Rev Neurosci        ISSN: 0334-1763            Impact factor:   4.353


  42 in total

1.  Obstructive sleep apnea severity correlates with cellular and plasma oxidative stress parameters and affective symptoms.

Authors:  C M R Franco; A M J Lima; L Ataíde; O G Lins; C M M Castro; A A Bezerra; M F de Oliveira; J R M Oliveira
Journal:  J Mol Neurosci       Date:  2012-03-09       Impact factor: 3.444

Review 2.  Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression.

Authors:  Michael Maes
Journal:  Metab Brain Dis       Date:  2012-07-07       Impact factor: 3.584

Review 3.  Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications.

Authors:  George Anderson; Michael Berk; Olivia Dean; Steven Moylan; Michael Maes
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 4.  Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research.

Authors:  Michael Maes; Gabriel Nowak; Javier R Caso; Juan Carlos Leza; Cai Song; Marta Kubera; Hans Klein; Piotr Galecki; Cristiano Noto; Enrico Glaab; Rudi Balling; Michael Berk
Journal:  Mol Neurobiol       Date:  2015-05-02       Impact factor: 5.590

Review 5.  Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology.

Authors:  Firdaus S Dhabhar
Journal:  Neuroimmunomodulation       Date:  2009-06-29       Impact factor: 2.492

Review 6.  The inflammation hypothesis in geriatric depression.

Authors:  George S Alexopoulos; Sarah Shizuko Morimoto
Journal:  Int J Geriatr Psychiatry       Date:  2011-03-02       Impact factor: 3.485

7.  Etazolate, a phosphodiesterase-4 enzyme inhibitor produces antidepressant-like effects by blocking the behavioral, biochemical, neurobiological deficits and histological abnormalities in hippocampus region caused by olfactory bulbectomy.

Authors:  Ankur Jindal; Radhakrishnan Mahesh; Shvetank Bhatt
Journal:  Psychopharmacology (Berl)       Date:  2014-08-15       Impact factor: 4.530

Review 8.  From stress to inflammation and major depressive disorder: a social signal transduction theory of depression.

Authors:  George M Slavich; Michael R Irwin
Journal:  Psychol Bull       Date:  2014-01-13       Impact factor: 17.737

Review 9.  Blood-Brain Barrier: COVID-19, Pandemics, and Cytokine Norms.

Authors:  Atmaram Yarlagadda; Samuel L Preston; Rachel P Jeyadhas; Adam Edward Lang; Rasha Hammamieh; Anita H Clayton
Journal:  Innov Clin Neurosci       Date:  2021-01-01

10.  Antidepressant-like effect of celecoxib piroxicam in rat models of depression.

Authors:  Ronise M Santiago; Janaína Barbiero; Bruno J Martynhak; Suelen L Boschen; Luisa M da Silva; Maria F P Werner; Claudio Da Cunha; Roberto Andreatini; Marcelo M S Lima; Maria A B F Vital
Journal:  J Neural Transm (Vienna)       Date:  2014-01-24       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.